Clinical Trial Update: Personalised Neoantigen-targeting Cancer Vaccine NECVAX-NEO1 in Neoadjuvant Triple-negative Breast Cancer [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 clinical trial investigating a personalized neoantigen-targeting cancer vaccine (NECVAX-NEO1) for neoadjuvant treatment in triple-negative breast ca…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• NECVAX-NEO1

Snippet

Sponsor: NEC Bio B.V | Conditions: Triple Negative Breast Cancer | Phase 1, Phase 2 | Status: RECRUITING